John Rim, Samsung Biologics president and CEO
June 8, 2023 09:54 AM EDTUpdated 11:51 AM
Deals
Manufacturing

Sam­sung Bi­o­log­ics se­cures $400M+ man­u­fac­tur­ing deal with Pfiz­er

Tyler Patchen

News Reporter

Sam­sung Bi­o­log­ics struck a deal with Pfiz­er to man­u­fac­ture the drug­mak­er’s biosim­i­lars port­fo­lio, in­clud­ing its prod­ucts for im­munol­o­gy, in­flam­ma­tion and on­col­o­gy, the South Ko­re­an com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Can Bill An­der­son save Bay­er?

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Drug pol­i­cy vet­er­an at CMS to de­part on Fri­day

CDC is in­ves­ti­gat­ing five hos­pi­tal­iza­tions af­ter use of Val­ne­va’s chikun­gun­ya vac­cine

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times